ONCO
vs
O
OMX Stockholm 30
ONCO
Over the past 12 months, ONCO has underperformed OMX Stockholm 30, delivering a return of -31% compared to the OMX Stockholm 30's +33% growth.
Stocks Performance
ONCO vs OMX Stockholm 30
Performance Gap
ONCO vs OMX Stockholm 30
Performance By Year
ONCO vs OMX Stockholm 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oncopeptides AB
Glance View
Oncopeptides AB is a pharmaceutical company focused on the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
